Verici Dx PLC (LSE:VRCI) Share Price

Company Profile

Business description
Verici Dx PLC is the development of prognostic and diagnostic tests for kidney transplant patients. It is a commercial stage diagnostics company, transforming the outcomes of kidney transplants through a complementary suite of proprietary, edge tests. These form a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. It has developed a suite of blood-based tests for kidney transplant patients. The group has one division being the development of prognostic and diagnostic tests for kidney transplant patients. The company's products are Tutivia, Clarava, Protega. The company's services are Next Generation Sequencing Services, Bioinformatics and Data Science Services.
Contact
19 Stanwell Road
Avon House
Penarth
CardiffCF64 2EZ
GBR
https://www.vericidx.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
22

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,752.31	58.95	-0.75%
DAX 40	25,156.73	215.02	-0.85%
Dow JONES (US)	52,867.98	11.89	0.02%
FTSE 100	10,665.86	59.17	-0.55%
HKSE	23,093.37	158.69	0.69%
NASDAQ	26,008.86	694.00	-2.60%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,663.43	93.74	-1.21%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%